Litcius/Paper detail

Outcome of chimeric antigen receptor T-cell therapy following treatment with inotuzumab ozogamicin in children with relapsed or refractory acute lymphoblastic leukemia

Valeria Ceolin, Erica Brivio, Harm van Tinteren, Susan R. Rheingold, Allison Barz Leahy, Britta Vormoor, Maureen M. O’Brien, Jeremy D. Rubinstein, Krzysztof Kałwak, Barbara De Moerloose, Elad Jacoby, Peter Bader, Monica López‐Duarte, Bianca F. Goemans, Franco Locatelli, Peter M. Hoogerbrugge, Friso Calkoen, C. Michel Zwaan

2022Leukemia28 citationsDOIOpen Access PDF

Topics & Concepts

MedicineMinimal residual diseaseCalicheamicinRefractory (planetary science)Internal medicineGastroenterologyCartChimeric antigen receptorCumulative incidenceLeukemiaImmunologySurgeryImmunotherapyAntibodyCancerTransplantationAstrobiologyEngineeringMechanical engineeringPhysicsCAR-T cell therapy researchAcute Lymphoblastic Leukemia researchVirus-based gene therapy research
Outcome of chimeric antigen receptor T-cell therapy following treatment with inotuzumab ozogamicin in children with relapsed or refractory acute lymphoblastic leukemia | Litcius